Chelidonine isolated from ethanolic extract of Chelidonium majus promotes apoptosis in HeLa cells through p38-p53 and PI3K/AKT signalling pathways

Journal of Chinese Integrative Medicine

Volumn 10, Issue 9, 2012, Pages 1025-1038

  Paul, Avijit ^a   Bishayee, Kausik ^a   Ghosh, Samrat ^a   Mukherjee, Avinaba ^a   Sikdar, Sourav ^a   Chakraborty, Debrup ^a   Boujedaini, Naoual ^b   Khuda Bukhsh, Anisur Rahman ^a  

^a UNIVERSITY OF KALYANI   (India)

^b Boiron Laboratory   (France)

Author keywords

Antineoplastic agents; Apoptosis; Chelidonine; Chelidonium majus; HeLa cells; Phytogenic; Signal transducing

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ALCOHOL; CHELIDONIUM EXTRACT; JANUS KINASE 3; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN E6; PROTEIN E7; PROTEIN P53; REACTIVE OXYGEN METABOLITE; STAT3 PROTEIN; SYNAPTOPHYSIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL PROLIFERATION; CHELIDONIUM; CIRCULAR DICHROISM; DNA DAMAGE; DOWN REGULATION; DRUG ISOLATION; FLOW CYTOMETRY; HELA CELL; LD 50; MITOCHONDRIAL MEMBRANE POTENTIAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; THYMUS; UPREGULATION; WESTERN BLOTTING;

APOPTOSIS; BENZOPHENANTHRIDINES; CELL CYCLE CHECKPOINTS; CELL PROLIFERATION; CHELIDONIUM; HELA CELLS; HUMANS; MEMBRANE POTENTIAL, MITOCHONDRIAL; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-BCL-2; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84867113607     PISSN: 16721977     EISSN: None     Source Type: Journal    
DOI: 10.3736/jcim20120912     Document Type: Article

References (46)

1. Chelidonium majus L. milky sap can induce apoptosis in human cervical carcinoma HeLa cells but not in Chinese Hamster Ovary CHO cells[J]. Folia Histochem Cytobiol, 2008, 46(1): 79-83.
2. Moro PA, Cassetti F, Giugliano G, Falce MT, Mazzanti G, Menniti-Ippolito F, Raschetti R, Santuccio C. Hepatitis from greater celandine (Chelidonium majus L.): review of literature and report of a new case[J]. J Ethnopharmacol, 2009, 124(2): 328-332.
3. Gilca M, Gaman L, Panait E, Stoian I, Atanasiu V. Chelidonium majus-an integrative review: traditional knowledge versus modern findings. Forsch Komplementmed. 2010; 17(5): 241-248.
4. Biswas SJ, Khuda-Bukhsh AR. Effect of a homeopathic drug, Chelidonium, in amelioration of p-DAB induced hepatocarcinogenesis in mice[J]. BMC Complement Altern Med, 2002, 2: 4.
5. Biswas SJ, Khuda-Bukhsh AR. Evaluation of protective potentials of a potentized homeopathic drug, Chelidonium majus, during azo dye induced hepatocarcinogenesis in mice. Indian J Exp Biol. 2004; 42(7): 698-714.
6. Biswas SJ, Bhattacharjee N, Khuda-Bukhsh AR. Efficacy of a plant extract (Chelidonium majus L.) in combating induced hepatocarcinogenesis in mice[J]. Food Chem Toxicol, 2008, 46(5): 1474-1487.
7. Kéry A, Horvth J, Nsz I, Verzr-Petri G, Kulcs G, Dn P. Antiviral alkaloid in Chelidonium majus L. Acta Pharm Hung. 1987; 57(1-2): 19-25.
8. Lenfeld J, Kroutil M, Marslek E, Slavík J, Preininger V, Simnek V. Antiinflammatory activity of quaternary benzophenanthridine alkaloids from Chelidonium majus. Planta Med. 1981; 43(2): 161-165.
9. Chelidonium majus L. (Papaveraceae)[J]. Pharmacol Res, 1996, 33(2): 127-134.
10. Chelidonium majus L. (Ukrain)[J]. Drugs Exp Clin Res, 1992, 18(Suppl): 63-67.
11. Zemskov V, Prokopchuk O, Susak Y, Zemskov S, Tkachenko O, Hodysh Y, Nowicky W. Efficacy of ukrain in the treatment of pancreatic cancer[J]. Langenbecks Arch Surg, 2002, 387(2): 84-89.
12. Uglyanitsa KN, Nechiporenko NA, Nefyodov LI, Doroshenko YM, Brzosko W, Nowicky W. Results of Ukrain monotherapy of prostate cancer[J]. Drugs Exp Clin Res, 2000, 26(5-6): 191-193.
13. Kadan P, Korsh OB, Melnyk A. Ukrain therapy of recurrent breast cancer with lung metastases (case report)[J]. Drugs Exp Clin Res, 1996, 22(3-5): 243-245.
14. Panzer A, Joubert AM, Bianchi PC, Seegers JC. The antimitotic effects of Ukrain, a Chelidonium majus alkaloid derivative, are reversible in vitro. Cancer Lett. 2000; 150(1): 85-92.
15. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics[J]. CA Cancer J Clin, 2011, 61(2): 69-90.
16. Green JA. Clinical trials in cancer[J]. Br J Cancer, 2011, 104(10): 1521-1522.
17. Chelidonium majus L. studied by different chromatographic techniques[J]. Chromatographia, 2006, 63(Suppl 13): S81-S86.
18. Kim YM, Talanian RV, Billiar TR. Nitric oxide inhibits apoptosis by preventing increases in caspase-3-like activity via two distinct mechanisms[J]. J Biol Chem, 1997, 272(49): 31138-31148.
19. Morley N, Rapp A, Dittmar H, Salter L, Gould D, Greulich KO, Curnow A. UVA-induced apoptosis studied by the new apo/necro-Comet-assay which distinguishes viable, apoptotic and necrotic cells[J]. Mutagenesis, 2006, 21(2): 105-114.
20. Biswas R, Mandal SK, Dutta S, Bhattacharyya SS, Boujedaini N, Khuda-Bukhsh AR. Thujone-rich fraction of Thuja occidentalis demonstrates major anti-cancer potentials: evidences from in vitro studies on A375 cells. Evid Based Complement Alternat Med. 2011; 2011: 568148.
21. Samadder A, Chakraborty D, De A, Bhattacharyya SS, Bhadra K, Khuda-Bukhsh AR. Possible signaling cascades involved in attenuation of alloxan-induced oxidative stress and hyperglycemia in mice by ethanolic extract of Syzygium jambolanum: drug-DNA interaction with calf thymus DNA as target[J]. Eur J Pharm Sci, 2011, 44(3): 207-217.
22. Mandal SK, Biswas R, Bhattacharyya SS, Paul S, Dutta S, Pathak S, Khuda-Bukhsh AR. Lycopodine from Lycopodium clavatum extract inhibits proliferation of HeLa cells through induction of apoptosis via caspase-3 activation[J]. Eur J Pharmacol, 2010, 626(2-3): 115-122.
23. Yang SE, Hsieh MT, Tsai TH, Hsu SL. Effector mechanism of magnolol-induced apoptosis in human lung squamous carcinoma CH27 cells[J]. Br J Pharmacol, 2003, 138(1): 193-201.
24. Bhattacharyya SS, Paul S, Mandal SK, Banerjee A, Boujedaini N, Khuda-Bukhsh AR. A synthetic coumarin (4-methyl-7 hydroxy coumarin) has anti-cancer potentials against DMBA-induced skin cancer in mice[J]. Eur J Pharmacol, 2009, 614(1-3): 128-136.
25. MacLean DB, Bell RA, Saunders JK, Chen CY, Manske RHF. Structures of three minor alkaloids of Fumaria officinalis L[J]. Can J Chem, 1969, 47(19): 3593-3599.
26. Isaacs JT. Apoptosis: translating theory to therapy for prostate cancer[J]. J Natl Cancer Inst, 2000, 92(17): 1367-1369.
27. Fruehauf JP, Meyskens FL Jr. Reactive oxygen species: a breath of life or death? Clin Cancer Res. 2007; 13(3): 789-794.
28. Lpez-Lzaro M. Dual role of hydrogen peroxide in cancer: possible relevance to cancer chemoprevention and therapy[J]. Cancer Lett, 2007, 252(1): 1-8.
29. Yip NC, Fombon IS, Liu P, Brown S, Kannappan V, Armesilla AL, Xu B, Cassidy J, Darling JL, Wang W. Disulfiram modulated ROS-MAPK and NFκB pathways and targeted breast cancer cells with cancer stem cell-like properties[J]. Br J Cancer, 2011, 104(10): 1564-1574.
30. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA, Bruncko M, Deckwerth TL, Dinges J, Hajduk PJ, Joseph MK, Kitada S, Korsmeyer SJ, Kunzer AR, Letai A, Li C, Mitten MJ, Nettesheim DG, Ng S, Nimmer PM, O'Connor JM, Oleksijew A, Petros AM, Reed JC, Shen W, Tahir SK, Thompson CB, Tomaselli KJ, Wang B, Wendt MD, Zhang H, Fesik SW, Rosenberg SH. An inhibitor of Bcl-2 family proteins induces regression of solid tumours[J]. Nature, 2005, 435(7042): 677-681.
31. Chaudhari M, Jayaraj R, Bhaskar AS, Lakshmana Rao PV. Oxidative stress induction by T-2 toxin causes DNA damage and triggers apoptosis via caspase pathway in human cervical cancer cells[J]. Toxicology, 2009, 262(2): 153-161.
32. Khan N, Afaq F, Syed DN, Mukhtar H. Fisetin, a novel dietary flavonoid, causes apoptosis and cell cycle arrest in human prostate cancer LNCaP cells[J]. Carcinogenesis, 2008, 29(5): 1049-1056.
33. Mauro MO, Sartori D, Oliveira RJ, Ishii PL, Mantovani MS, Ribeiro LR. Activity of selenium on cell proliferation, cytotoxicity, and apoptosis and on the expression of CASP9, BCL-XL and APC in intestinal adenocarcinoma cells[J]. Mutat Res, 2011, 715(1-2): 7-12.
34. Tsujimoto Y, Shimizu S. Bcl-2 family: life-or-death switch[J]. FEBS Lett, 2000, 466(1): 6-10.
35. Martinou JC, Desagher S, Antonsson B. Cytochrome c release from mitochondria: all or nothing[J]. Nat Cell Biol, 2000, 2(3): E41-E43.
36. Hong SJ, Dawson TM, Dawson VL. Nuclear and mitochondrial conversations in cell death: PARP-1 and AIF signaling[J]. Trends Pharmacol Sci, 2004, 25(5): 259-264.
37. Enari M, Sakahira H, Yokoyama H, Okawa K, Iwamatsu A, Nagata S. A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD[J]. Nature, 1998, 391(6662): 43-50.
38. Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, Greenberg ME. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery[J]. Cell, 1997, 91(2): 231-241.
39. Grad JM, Zeng XR, Boise LH. Regulation of Bcl-xL: a little bit of this and a little bit of STAT[J]. Curr Opin Oncol, 2000, 12(6): 543-549.
40. Lowe SW, Lin AW. Apoptosis in cancer[J]. Carcinogenesis, 2000, 21(3): 485-495.
41. Chandarlapaty S, Sawai A, Scaltriti M, Rodrik-Outmezguine V, Grbovic-Huezo O, Serra V, Majumder PK, Baselga J, Rosen N. AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity[J]. Cancer Cell, 2011, 19(1): 58-71.
42. Fehrmann F, Laimins LA. Human papillomaviruses: targeting differentiating epithelial cells for malignant transformation[J]. Oncogene, 2003, 22(33): 5201-5207.
43. Zhang C, Zhu H, Yang X, Lou J, Zhu D, Lu W, He Q, Yang B. P53 and p38 MAPK pathways are involved in MONCPT-induced cell cycle G2/M arrest in human non-small cell lung cancer A549[J]. J Cancer Res Clin Oncol, 2010, 136(3): 437-445.
44. Wagner EF, Nebreda AR. Signal integration by JNK and p38 MAPK pathways in cancer development[J]. Nat Rev Cancer, 2009, 9(8): 537-549.
45. Tanaka Y, Gavrielides MV, Mitsuuchi Y, Fujii T, Kazanietz MG. Protein kinase C promotes apoptosis in LNCaP prostate cancer cells through activation of p38 MAPK and inhibition of the Akt survival pathway[J]. J Biol Chem, 2003, 278(36): 33753-33762.
46. Ahmed ST, Mayer A, Ji JD, Ivashkiv LB. Inhibition of IL-6 signaling by a p38-dependent pathway occurs in the absence of new protein synthesis[J]. J Leukoc Biol, 2002, 72(1): 154-162